Advertisement
Advertisement
CLLS
Cellectis S.A. - ADR
3.50
USDSponsored
-0.02
-0.57%
May 22, 16:00 UTC -4
Closed
After-Market
3.50
0.00
0.00%
CLLS Earnings Reports
Positive Surprise Ratio
CLLS beat 16 of 23 last estimates.
70%
Next Report
Date of Next Report
Aug 03, 2026
Estimate for Q2 26 (Revenue/ EPS)
$14.83M
/-$0.32
Implied change from Q1 26 (Revenue/ EPS)
+96.48%
/+77.78%
Implied change from Q2 25 (Revenue/ EPS)
-18.49%
/+33.33%
Cellectis S.A. - ADR earnings per share and revenue
On May 11, 2026, CLLS reported earnings of -0.18 USD per share (EPS) for Q1 26, beating the estimate of -0.28 USD, resulting in a 36.03% surprise. Revenue reached 7.55 million, compared to an expected 12.63 million, with a -40.26% difference. The market reacted with a -0.50% price change (close before vs. close after earnings).
Looking ahead to Q2 26, 6 analysts forecast an EPS of -0.32 USD, with revenue projected to reach 14.83 million USD, implying an increase of 77.78% EPS, and increase of 96.48% in Revenue from the last quarter.
Industry Peers’ Earnings
Industry Peers' Earnings displays EPS earnings data from companies in the same industry. Click on a card to view more details.
Compugen Ltd
Report Date
May 18, 2026 For Q1 26
Estimate
-$0.07
Actual
-$0.08
Surprise
-8.11%
Scilex Holding Company Common Stock
Report Date
May 20, 2026 For Q1 26
Estimate
-Actual
-$4.76
Surprise
-
Instil Bio, Inc. Common Stock
Report Date
May 15, 2026 For Q1 26
Estimate
-$0.59
Actual
-$0.62
Surprise
-4.04%
Immunovant, Inc. Common Stock
Report Date
May 20, 2026 For Q4 26
Estimate
-$0.61
Actual
-$0.73
Surprise
-19.11%
Sensei Biotherapeutics, Inc. Common Stock
Report Date
May 15, 2026 For Q1 26
Estimate
-$0.63
Actual
-$28.79
Surprise
-4452.50%
Neuphoria Therapeutics Inc. Common Stock
Report Date
May 15, 2026 For Q3 26
Estimate
-$0.98
Actual
-$0.09
Surprise
+90.90%
Cocrystal Pharma, Inc. Common Stock
Report Date
May 15, 2026 For Q1 26
Estimate
-$0.15
Actual
-$0.17
Surprise
-11.11%
Allarity Therapeutics, Inc. Common Stock
Report Date
May 15, 2026 For Q1 26
Estimate
-$0.22
Actual
-$0.17
Surprise
+24.24%
Akari Therapeutics plc ADR (0.01 USD)
Report Date
May 19, 2026 For Q1 26
Estimate
-$1.40
Actual
-$1.57
Surprise
-11.81%
EVOGENE LTD.
Report Date
May 20, 2026 For Q1 26
Estimate
-$0.27
Actual
-$0.60
Surprise
-117.86%
FAQ
What were Cellectis S.A. - ADR's earnings and revenue for the latest quarter Q1 2026?
For Q1 2026, Cellectis S.A. - ADR reported EPS of -$0.18, beating estimates by 36.03%, and revenue of $7.55M, -40.26% below expectations.
How did the market react to Cellectis S.A. - ADR's Q1 2026 earnings?
The stock price moved down -0.5%, changed from $3.98 before the earnings release to $3.96 the day after.
When is Cellectis S.A. - ADR expected to report next?
The next earning report is scheduled for Aug 03, 2026.
What are the forecasts for Cellectis S.A. - ADR's next earnings report?
Based on 6
analysts, Cellectis S.A. - ADR is expected to report EPS of -$0.32 and revenue of $14.83M for Q2 2026.
Which companies are reporting earnings today?
Check FXEmpire's Earnings Calendar for today's list of reporting companies.
Advertisement